Uterine adenosarcoma: An analysis on management, outcomes, and risk factors for recurrence

Gynecologic Oncology

Volumn 135, Issue 3, 2014, Pages 455-461

  Carroll, Amy ^a   Ramirez, Pedro T ^a   Westin, Shannon N ^a   Soliman, Pamela T ^a   Munsell, Mark F ^a   Nick, Alpa M ^a   Schmeler, Kathleen M ^a   Klopp, Ann H ^a   Fleming, Nicole D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenosarcoma; Sarcomatous overgrowth; Uterine sarcoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; VINCRISTINE;

ADENOSARCOMA; ADOLESCENT; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CHEMORADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; OVARIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; UTERINE ADENOSARCOMA; UTERUS TUMOR; VERY ELDERLY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE; UTERINE NEOPLASMS; YOUNG ADULT;

ADENOSARCOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 84920719228     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.10.022     Document Type: Article

References (20)

1. D'Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol 2009;40(11):1571-85.
2. Krivak TC, Seidman JD, McBroom JW, et al. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol 2001;83(1):89-94.
3. Clement PB. Mullerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases. Am J Surg Pathol 1989;13(1):28-38.
4. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010;116(1):131-9.
5. Kaku T, Silverberg SG, Major FJ, et al. Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. Int J Gynecol Pathol 1992;11(2):75-88.
6. Arend R, Bagaria M, Lewin SN, et al. Long-term outcome and natural history of uterine adenosarcomas. Gynecol Oncol 2010;119(2):305-8.
7. Tanner EJ, Toussaint T, Leitao Jr MM, et al. Management of uterine adenosarcoma with and without sarcomatous overgrowth. Gynecol Oncol 2013;129(1):140-4.
8. Zaloudek CJ, Norris HJ. Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases. Cancer 1981;48(2):354-66.
9. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol 1990;21(4):363-81.
10. Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009;104(3):177-8.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:499-503.
12. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
13. Gooley TA, Leisenring W, Crowley, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
15. Brooks SE, Zhan M, Cote T, et al. Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004;93(1):204-8.
16. Amant F, Schurmans K, Steenkiste E, et al. Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma. Gynecol Oncol 2004;93(3):680-5.
17. Soslow RA, Ali A, Oliva E. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol 2008;32(7):1013-21.
18. Hines BJ, Porges RF, Mittal K, et al. Use ofmedroxyprogesterone acetate in the treatment of Mullerian adenosarcoma: a case report. Gynecol Oncol 2002;85(1):192-5.
19. Lee SJ, Bae JH, Kim DC, et al. Oral progesterone treatment in a young woman with mullerian adenosarcoma whose ovary was preserved: a case report. Int J Gynecol Cancer 2010;20(7):1222-4.
20. Verschraegen CF, Vasuratna A, Edwards C, et al. Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer experience. Oncol Rep 1998;5(4):939-44.